Gene: GLIPR2
Official Full Name: GLI pathogenesis related 2provided by HGNC
Gene Summary: Enables protein homodimerization activity. Involved in positive regulation of ERK1 and ERK2 cascade; positive regulation of epithelial cell migration; and positive regulation of epithelial to mesenchymal transition. Located in Golgi membrane. Biomarker of pancreatic ductal adenocarcinoma. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO21894 | GLIPR2 Knockout cell line (HeLa) | Human | GLIPR2 | 1:3~1:6 | Negative | Online Inquiry |
KO21895 | GLIPR2 Knockout cell line (HCT 116) | Human | GLIPR2 | 1:2~1:4 | Negative | Online Inquiry |
KO21896 | GLIPR2 Knockout cell line (HEK293) | Human | GLIPR2 | 1:3~1:6 | Negative | Online Inquiry |
KO21897 | GLIPR2 Knockout cell line (A549) | Human | GLIPR2 | 1:3~1:4 | Negative | Online Inquiry |
GLIPR2 Gene Knockout Cell Lines are genetically engineered cell lines in which the GLIPR2 gene has been selectively disrupted or knocked out to study its functional implications in various biological processes. The GLIPR2 (GLI Pathway Regulated 2) gene is known for its role in cellular differentiation, apoptosis, and potentially in tumorigenesis. These knockout cell lines facilitate the investigation of GLIPR2’s contributions to cellular pathways, making them invaluable tools in both basic and applied research settings.
The primary mechanism of action for these knockout cell lines lies in the absence of the GLIPR2 protein, which allows researchers to observe changes in cellular behavior, gene expression profiles, and protein interactions that occur when GLIPR2 function is lost. By utilizing advanced CRISPR-Cas9 technology or other gene-editing methods, these cell lines provide a reliable model system for dissecting the pathways influenced by GLIPR2, thereby elucidating its role in diseases such as cancer and neurodevelopmental disorders.
The scientific importance of GLIPR2 Gene Knockout Cell Lines is underscored by their applications in a variety of research contexts, including drug discovery, molecular biology, and translational studies. Understanding the functional impact of GLIPR2 can lead to the identification of novel therapeutic targets and strategies, making these cell lines important for both academic and pharmaceutical research laboratories.
Unlike other gene knockout tools, GLIPR2 Gene Knockout Cell Lines offer specific advantages including consistent genetic modification that allows for reproducibility in experiments. Additionally, they provide a platform for high-throughput screening of compounds and the investigation of complex cellular responses without the confounding effects often seen in partial knockdowns or overexpression studies.
Researchers and clinicians looking to advance their understanding of cancer biology, gene regulation, and cellular mechanisms will find GLIPR2 Gene Knockout Cell Lines to be an essential asset in their toolkit. The ability to precisely study the loss of this gene can lead to breakthrough insights and potential therapeutic avenues.
Our company specializes in state-of-the-art genetic tools and models for bioresearch, providing high-quality, validated cell lines that empower researchers to make significant discoveries in the field of molecular biology. With our expertise in cellular genetics, we are committed to supporting the scientific community with innovative products designed for impactful research outcomes.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.